Psychometric Cognitive Decline Precedes the Advent of Subjective Cognitive Decline in the Evolution of Alzheimer's Disease.


Journal

Dementia and geriatric cognitive disorders
ISSN: 1421-9824
Titre abrégé: Dement Geriatr Cogn Disord
Pays: Switzerland
ID NLM: 9705200

Informations de publication

Date de publication:
2020
Historique:
received: 06 02 2020
accepted: 16 03 2020
pubmed: 11 5 2020
medline: 26 1 2021
entrez: 11 5 2020
Statut: ppublish

Résumé

We have described the clinical stages of the brain aging and Alzheimer's disease (AD) continuum. In terms of the pre-dementia stages of AD, we introduced the terminology "mild cognitive impairment" (MCI) for the first pre-dementia stage and "subjective cognitive decline" (SCD) for the pre-MCI stage. We now report the characteristics of a pre-SCD condition eventuating in likely AD. The aim of this study was to characterize a pre-SCD condition eventuating in AD. Sixty healthy persons with "no cognitive decline" (NCD) were recruited and 47 were followed (mean baseline age, 64.1 ± 8.9 years; mean follow-up time, 6.7 ± 3.1 years). Outcome was determined at the final assessment prior to 2002 as "decliner," if SCD or worse, or "nondecliner" if NCD. After controlling for age, gender, years of education, and follow-up time, there was a between-group difference in the decline rate (p < 0.001). Also, after controlling for demographic variables and follow-up time, the combinatorial psychometric score was lower at baseline in the future decliners (p = 0.035). Of the 9 psychometric variables, after controlling for demographic variables and follow-up time, 3 were significantly lower at baseline in future decliners. Since AD is known to be age related and all subjects in this study were otherwise healthy, we also did an analysis without controlling for age. The combinatorial psychometric score was highly significantly better at baseline in the future nondecliners than in the future decliners (p = 0.008). This is ostensibly the first study to link psychometric cognitive decline to the subsequent SCD stage of eventual AD.

Sections du résumé

BACKGROUND
We have described the clinical stages of the brain aging and Alzheimer's disease (AD) continuum. In terms of the pre-dementia stages of AD, we introduced the terminology "mild cognitive impairment" (MCI) for the first pre-dementia stage and "subjective cognitive decline" (SCD) for the pre-MCI stage. We now report the characteristics of a pre-SCD condition eventuating in likely AD.
OBJECTIVE
The aim of this study was to characterize a pre-SCD condition eventuating in AD.
METHOD
Sixty healthy persons with "no cognitive decline" (NCD) were recruited and 47 were followed (mean baseline age, 64.1 ± 8.9 years; mean follow-up time, 6.7 ± 3.1 years). Outcome was determined at the final assessment prior to 2002 as "decliner," if SCD or worse, or "nondecliner" if NCD.
RESULTS
After controlling for age, gender, years of education, and follow-up time, there was a between-group difference in the decline rate (p < 0.001). Also, after controlling for demographic variables and follow-up time, the combinatorial psychometric score was lower at baseline in the future decliners (p = 0.035). Of the 9 psychometric variables, after controlling for demographic variables and follow-up time, 3 were significantly lower at baseline in future decliners. Since AD is known to be age related and all subjects in this study were otherwise healthy, we also did an analysis without controlling for age. The combinatorial psychometric score was highly significantly better at baseline in the future nondecliners than in the future decliners (p = 0.008).
CONCLUSION
This is ostensibly the first study to link psychometric cognitive decline to the subsequent SCD stage of eventual AD.

Identifiants

pubmed: 32388509
pii: 000507286
doi: 10.1159/000507286
pmc: PMC8846443
mid: NIHMS1585407
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

16-21

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001445
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR000096
Pays : United States
Organisme : NIMH NIH HHS
ID : P50 MH043486
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR029893
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG008051
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG012101
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG003051
Pays : United States

Informations de copyright

© 2020 S. Karger AG, Basel.

Références

J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
Alzheimers Dement. 2019 Mar;15(3):465-476
pubmed: 30555032
Acta Psychiatr Scand. 2014 Dec;130(6):439-51
pubmed: 25219393
Alzheimers Dement. 2010 Jan;6(1):11-24
pubmed: 20129317
Ann Neurol. 1990 Apr;27(4):428-37
pubmed: 2353798
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S63-86
pubmed: 26402085
Am J Psychiatry. 1982 Sep;139(9):1136-9
pubmed: 7114305
Neurobiol Aging. 2006 Mar;27(3):471-81
pubmed: 16213630
Ann Neurol. 1980 May;7(5):486-8
pubmed: 7396427
Alzheimers Dement. 2017 Mar;13(3):296-311
pubmed: 27825022
Geriatrics. 1986 Apr;41(4):30-46
pubmed: 3949165
J Clin Psychiatry. 1987 May;48 Suppl:9-15
pubmed: 3553166
JAMA. 1995 May 3;273(17):1354-9
pubmed: 7715060
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Int Psychogeriatr. 2008 Feb;20(1):1-16
pubmed: 18072981
J Gerontol. 1971 Jan;26(1):70-5
pubmed: 5540322
BMJ. 2012 Jan 05;344:d7622
pubmed: 22223828

Auteurs

Barry Reisberg (B)

Department of Psychiatry, NYU Langone Health, New York, New York, USA, barry.reisberg@nyumc.org.

Yongzhao Shao (Y)

Department of Population Health, NYU Langone Health, New York, New York, USA.

Mesum Moosavi (M)

Department of Psychiatry, NYU Langone Health, New York, New York, USA.

Sunnie Kenowsky (S)

Department of Psychiatry, NYU Langone Health, New York, New York, USA.

Alok Vedvyas (A)

Department of Neurology, NYU Langone Health, New York, New York, USA.

Karyn Marsh (K)

Department of Neurology, NYU Langone Health, New York, New York, USA.

Jia Bao (J)

Department of Population Health, NYU Langone Health, New York, New York, USA.

Maja Buj (M)

Department of Psychiatry, NYU Langone Health, New York, New York, USA.

Carol Torossian (C)

Department of Psychiatry, NYU Langone Health, New York, New York, USA.

Alan Kluger (A)

Department of Neurology, NYU Langone Health, New York, New York, USA.

Gaurav Vedvyas (G)

Department of Neurology, NYU Langone Health, New York, New York, USA.

Thet Oo (T)

Department of Neurology, NYU Langone Health, New York, New York, USA.

Fawad Malik (F)

Department of Pharmacy, Bellevue Hospital, New York, New York, USA.

Fauzia Arain (F)

Department of Psychiatry, NYU Langone Health, New York, New York, USA.

Arjun V Masurkar (AV)

Department of Neurology, NYU Langone Health, New York, New York, USA.

Thomas Wisniewski (T)

Department of Psychiatry, NYU Langone Health, New York, New York, USA.
Department of Neurology, NYU Langone Health, New York, New York, USA.
Department of Pathology, NYU Langone Health, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH